RT Journal Article
SR Electronic
T1 Efficacy and safety of SARS-CoV-2 revaccination in non-responders with immune-mediated inflammatory disease
JF Annals of the Rheumatic Diseases
JO Ann Rheum Dis
FD BMJ Publishing Group Ltd and European League Against Rheumatism
SP 1023
OP 1027
DO 10.1136/annrheumdis-2021-221554
VO 81
IS 7
A1 Simon, David
A1 Tascilar, Koray
A1 Fagni, Filippo
A1 Schmidt, Katja
A1 Krönke, Gerhard
A1 Kleyer, Arnd
A1 Ramming, Andreas
A1 Schoenau, Verena
A1 Bohr, Daniela
A1 Knitza, Johannes
A1 Harrer, Thomas
A1 Manger, Karin
A1 Manger, Bernhard
A1 Schett, Georg
YR 2022
UL http://ard.bmj.com/content/81/7/1023.abstract
AB Objectives To test whether patients with immune-mediated inflammatory disease (IMIDs), who did not respond to two doses of the SARS-CoV-2 vaccine, develop protective immunity, if a third vaccine dose is administered.Methods Patients with IMID who failed to seroconvert after two doses of SARS-CoV-2 vaccine were subjected to a third vaccination with either mRNA or vector-based vaccines. Anti-SARS-CoV-2 IgG, neutralising activity and T cell responses were assessed at baseline and 3 weeks after revaccination and also evaluated seprarately in rituximab (RTX) and non-RTX exposed patients.Results 66 non-responders were recruited, 33 treated with RTX, and 33 non-exposed to RTX. Overall, 49.2% patients seroconverted and 50.0% developed neutralising antibody activity. Seroconversion (78.8% vs 18.2%) and neutralising activity (80.0% vs 21.9%) was higher in non-RTX than RTX-treated patients with IMID, respectively. Humoral vaccination responses were not different among patients showing positive (59.3%) or negative (49.7%) T cell responses at baseline. Patients remaining on mRNA-based vaccines showed similar vaccination responses compared with those switching to vector-based vaccines.Conclusions Overall, these data strongly argue in favor of a third vaccination in patients with IMID lacking response to standard vaccination irrespective of their B cell status.Data are available on reasonable request. N/A.